

APPROVED DRUG PRODUCTS

With Therapeutic Equivalence Evaluations




The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

The University
of Michigan
Pharmacy
Library

**CUMULATIVE
SUPPLEMENT 2**
AUG '82 - OCT '82



**APPROVED
PRESCRIPTION
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

3RD EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
NATIONAL CENTER FOR DRUGS AND BIOLOGICS

Digitized by **Google**

Original from
UNIVERSITY OF MICHIGAN

REFERENCE
DOES NOT REMOVE

PHARMACY
R371
307
B673
3rd ed.
Suppl. 2

SERIAL
REFERENCE

MAN 2.4 1983
UNIVERSITY OF MICHIGAN
LIBRARIES

UNIVERSITY OF MICHIGAN
LIBRARIES

1982

DEPOSITED BY THE
UNITED STATES OF AMERICA

Digitized by Google

Original from
UNIVERSITY OF MICHIGAN

FOOD AND DRUG ADMINISTRATION
APPROVED PRESCRIPTION DRUG PRODUCTS
WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS
CUMULATIVE SUPPLEMENT

I. PREFACE

This cumulative supplement is one of a series of monthly updates to the Approved Prescription Drug Products with Therapeutic Equivalence Evaluations, 3rd Edition, (the List) to cover interim revisions to the annual publication of the List in its entirety. The List is comprised of several parts and some by their nature are identified by the term "list". The cumulative supplements routinely provide updates to two of these lists: The Drug Product List and the Addendum: DESI Pending List.

The List cannot be used effectively without the current cumulative supplement. Users may wish to place an asterisk (*) in the List to the left of the ingredient(s) in the Drug Product List and the product name in the Addendum to indicate that changes to that entry appear in the cumulative supplement. It is also suggested that earlier cumulative supplements be discarded to avoid possible confusion. In this way, only the List and current cumulative supplement need be referenced.

A. DRUG PRODUCT LIST

The Drug Product List cumulative supplements include the changes made since August 1, 1982. Each subsequent cumulative supplement replaces the previous month's cumulative supplement.

Information in this cumulative supplement follows the format of the Drug Product List. The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Context information on drug products is provided in each cumulative supplement for completeness to assist in locating the proper place in the Drug Product List for the revision. (Strength(s) which already exist in the publication will not be repeated for context.) A page number in parentheses referring to the Drug Product List is located to the right of the ingredient(s).

Additions to the Drug Product List are indicated by new information in the cumulative supplement. Additions new to the current cumulative supplement are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is dropped in subsequent cumulative supplements for that item.

Deletions from the Drug Product List are indicated by overstruck print in the cumulative supplement. Deletions new to the current cumulative supplement are indicated by the symbol >D.I.> (DELETE) to the left of the line containing the overstruck print. The >D.I.T.> symbol is dropped in subsequent cumulative supplements for that item.

A newly approved product is identified by the lozenge (⌘) to the right of its strength. This identifier remains throughout all cumulative supplements for this edition.

B. ADDENDUM: DESI Pending List

Information in this cumulative supplement follows the format of the Addendum. Additions and deletions are indicated in the same manner as in the cumulative supplement to the Drug Product List. A change in Current Status of a DESI product is also indicated by an addition and a deletion.

II. SPECIAL NOTES

A. INDICES AND ABBREVIATIONS:

STANDARD TERMS:

Added Route of Administration: INTRAPERITONEAL

B. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

Categories of counts derived from product information in the Drug Product List and from this cumulative supplement are presented. The format of this report was modified this month to include counts of new molecular entities (NME) and salts, esters and derivatives of NME's approved by the agency each month during the past quarter.

III. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

DESCRIPTION OF REPORT

The following report provides summary counts derived from product information in the Drug Product List and the current cumulative supplement. The counts appear in two sections. Section A. refers to the products in the List and Section B. to products in the current cumulative supplement. A new column of data will appear in Section A. each three-month period following July '82. Section A. therefore will provide baseline and quarterly data while Section B. provides monthly activity.

USE OF REPORT

From the data presented, users should be able to observe such things as (1) newly approved, DESI effective and remarketed drug products which are added to the List; (2) products that are being removed from the List as the result of withdrawal of approval, changes from prescription to over-the-counter status and discontinued marketing of products; and, (3) trends in products as either multisource or single source.

Drug Product Definition

For this report, a drug product is the representation in the Drug Product List of an active moiety (includes molecular entity and its salts, esters and derivatives) either as a single entity or as a combination product, provided in a specific dosage form and strength for a given route of administration marketed by a firm under a particular generic or trade name.

New Molecular Entity

The active moiety has not previously been approved in the United States for use in a drug product either as a single ingredient or part of a combination.

Drug Product Count

This report provides counts in several categories from the list composed of domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Counts of products still pending in the DESI review are not provided. Excluded also are those approved drug products marketed by distributors; those marketed solely abroad; and products now regarded as medical devices, biologics or foods. Also not included in the counts are those duplicate products of a given applicant whose only distinguishing characteristics are items such as package size, inactive ingredient(s), color and alternate manufacturing sites. These various counts are excluded because the Drug Product List itself excludes products from these categories.

(1) THERAPEUTIC EQUIVALENCE EVALUATIONS PROVIDED ONLY FOR MULTISOURCE PRODUCTS (1-00, AVAILABLE FROM MORE THAN ONE APPLICANT)
(2) AMINO ACID-CONTAINING PRODUCTS OF VARYING COMPOSITION (SEE PAGE 2-8 OF THE LIST)

	AUG-SEPT '82	OCT '82	CUMULATIVE
DRUG PRODUCTS ADDED:	85	44	129
NEWLY APPROVED	85	43	128
DESI EFFECTIVE	0	0	0
REMARKED	0	1	1
DRUG PRODUCTS REMOVED:	18	21	39
WITHDRAWN APPROVAL	0	0	0
RX TO OTC SWITCH	2	0	2
DISCONTINUED MARKETING	16	21	37
NET GAIN IN DRUG PRODUCTS	67	23	90
NEW SINGLE SOURCE PRODUCTS	26	14	40
NEW MULTISOURCE DRUG PRODUCTS	59	30	89
NEWLY APPROVED MOLECULAR ENTITIES:	7	2	9
NEW MOLECULAR ENTITIES (NME'S)	6	2	8
NEW SALTS, ESTERS AND DERIVATIVES			
OF PREVIOUSLY APPROVED NME'S	0	0	0

B. ACTIVITY FOR SUPPLEMENT NUMBER 2 AND CUMULATIVE SINCE JULY '82

	JULY '82
DRUG PRODUCTS LISTED	6303
SINGLE SOURCE	1885 (30%)
MULTISOURCE (1)	4418 (70%)
THERAPEUTICALLY EQUIVALENT	3456 (54.8%)
NOT THERAPEUTICALLY EQUIVALENT	954 (15.1%)
EXCEPTIONS (2)	8 (0.1%)
NUMBER OF APPLICANTS	303

A. COUNTS CUMULATIVE BY QUARTERS

CATEGORIES COUNTED

REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

ACETAMINOPHEN; CODEINE PHOSPHATE (PAGE 3-1)

TABLET; ORAL
ACETAMINOPHEN W/ CODEINE PHOSPHATE
 > DLT > /AA/ /CARNRICK/5M CARNRICK/325MG;30MG/

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE (PAGE 3-2)

TABLET; ORAL
 TALACEN
 STERLING DRUG 650MG;EQ 25MG BASEM

ACETAZOLAMIDE (PAGE 3-3)

TABLET; ORAL
ACETAZOLAMIDE
 > ADD > AB ASCOT HOSP PHARMS 250MG

> ADD > ACYCLOVIR SODIUM (PAGE 3-4)

> ADD > INJECTABLE; INJECTION
 > ADD > ZOVIRAX
 > ADD > BURROUGHS WELLCOME EQ 500MG BASE/VIALM

> DLT > ALUMINUM CHLORHYDROXY ALLANTOINATE; PREDNISOLONE (PAGE 3-5)

> DLT > /CREAM; TOPICAL/
 > DLT > /METI-DERM/
 > DLT > /SCHERING/ 10.25%;0.5% /

> DLT > ALUMINUM NICOTINATE (PAGE 3-5)

> DLT > /TABLET; ORAL/
 > DLT > /NICALIN/
 > DLT > /VERRELL POW POW CHEN/625MG/

AMINO ACIDS (PAGE 3-6)

INJECTABLE; INJECTION
 > ADD > HEPATAMINE 8%
 > ADD > AM MCGAW/AM HOSP 8%
 NOVAMINE 8.5%
 CUTTER LABORATORIES 8.5%
 NOVAMINE 11.4%
 CUTTER LABORATORIES 11.4%
 > ADD > RENAMIN W/O ELECTROLYTES
 > ADD > TRAVENOL LABS .5%

AMINOCAPROIC ACID (PAGE 3-7)

INJECTABLE; INJECTION

AMICAR
 > ADD > AP LEDERLE PARENTERALS 250MG/ML
 > ADD > AMINOCAPROIC ACID
 > ADD > AP ELKINS-SINN/AHROBINS 250MG/MLM

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE (PAGE 3-11)

CAPSULE; ORAL

DELCOBES
 /DECCA CHEMICAL/ /1.25MG;1.25MG;1.25MG;1.25MG/
 /2.5MG;2.5MG;2.5MG;2.5MG/
 /3.75MG;3.75MG;3.75MG;3.75MG/
 /5MG;5MG;5MG;5MG/
 LEMMON
 1.25MG;1.25MG;1.25MG;1.25MG
 2.5MG;2.5MG;2.5MG;2.5MG
 3.75MG;3.75MG;3.75MG;3.75MG
 5MG;5MG;5MG;5MG

TABLET; ORAL

DELCOBES
 /DECCA CHEMICAL/ /1.25MG;1.25MG;1.25MG;1.25MG/
 /2.5MG;2.5MG;2.5MG;2.5MG/
 /3.75MG;3.75MG;3.75MG;3.75MG/
 /5MG;5MG;5MG;5MG/
 LEMMON
 1.25MG;1.25MG;1.25MG;1.25MG
 2.5MG;2.5MG;2.5MG;2.5MG
 3.75MG;3.75MG;3.75MG;3.75MG
 5MG;5MG;5MG;5MG

ASPIRIN; CAFFEINE; PHENACETIN; PROPOXYPHENE HYDROCHLORIDE (PAGE 3-15)

CAPSULE; ORAL

/PROPOXYPHENE HCL COMPOUND 65/
 /AA/ /ROXANE LABORATORIES/ 227MG;32.4MG;162MG;65MG/

AZLOCILLIN SODIUM (PAGE 3-17)

INJECTABLE; INJECTION

AZLIN
 MILES PHARMS/MILES EQ 2GM BASE/VIALM
 EQ 3GM BASE/VIALM
 EQ 4GM BASE/VIALM

CHLORTHALIDONE (PAGE 3-37)

TABLET; ORAL
CHLORTHALIDONE
 > ADD > AB ASCOT HOSP PHARMS 25MG
 > ADD > AB ASCOT HOSP PHARMS 50MG

CHLORZOXAZONE (PAGE 3-37)

TABLET; ORAL
CHLORZOXAZONE
 AA CHELSEA LABORATORIES 250MG

CYCLOPHOSPHAMIDE (PAGE 3-44)

INJECTABLE; INJECTION
CYTOKAN
 MEAD JOHNSON/B-M 1GM/VIAL
 2GM/VIAL

CYPROHEPTADINE HYDROCHLORIDE (PAGE 3-44)

TABLET; ORAL
CYPROHEPTADINE HCL
 > ADD > AA ASCOT HOSP PHARMS 4MG
 /23/ /LEPHERIE LABS/ /4MG/
 AA LEHMAN 4MG

DEXAMETHASONE (PAGE 3-47)

TABLET; ORAL
DEXAMETHASONE
 > DLT > /BP/ /LEPHERIE LABS/ /1.5MG/
 > DLT > /BP/ /LEPHERIE LABS/ /1.5MG/
 ROXANE LABORATORIES 2MG

DEXAMETHASONE SODIUM PHOSPHATE (PAGE 3-48)

INJECTABLE; INJECTION
DEXAMETHASONE
 AP ELKINS-SINN/AHROBINS EQ 4MG PHOSPHATE/ML
 AP EQ 10MG PHOSPHATE/ML
DEXAMETHASONE SODIUM PHOSPHATE
 /46/ /ELKINS-SINN/AHROBINS/ EQ 4MG PHOSPHATE/ML

SOLUTION/DROPS; OPHTHALMIC
DEXAMETHASONE SODIUM PHOSPHATE
 > DLT > /AT/ BARNES-HIND PHARMS EQ 0.1% PHOSPHATE
 > DLT > /AT/ MAURRY BIOLOGICAL EQ 0.1% PHOSPHATE

DEXAMETHASONE SODIUM PHOSPHATE (PAGE 3-48)

SOLUTION/DROPS; OPHTHALMIC, OTIC
DECADRON
 > ADD > AT MSD MERCK EQ 0.1% PHOSPHATE
 > ADD > DEXAMETHASONE SODIUM PHOSPHATE
 > ADD > AT MAURRY BIOLOGICAL EQ 0.1% PHOSPHATE

/DEXOROPHENTRANINE MALEATE; PSEUDOEPHEDRINE SULFATE/ (PAGE 3-49)

/TABLET; ORAL/
 /PISOPHROL/
 /SCHERING/ /2MG;60MG/
 /TABLET; CONTROLLED RELEASE; ORAL/
 /PISOPHROL/
 /SCHERING/ /6MG;120MG/

DIATRIZOATE MEGLUMINE (PAGE 3-54)

INJECTABLE; INJECTION
ANGIOVIST 282
 AP BERLEX/SCHERING AG 602M
UROVIST MEGLUMINE DIU/CT
 AP BERLEX/SCHERING AG 302M
 SOLUTION; URETHRAL
UROVIST CYSTO
 AT BERLEX/SCHERING AG 302M
UROVIST CYSTO PEDIATRIC
 AT BERLEX/SCHERING AG 302M

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM (PAGE 3-54)

INJECTABLE; INJECTION
ANGIOVIST 202
 AP BERLEX/SCHERING AG 522;82M
ANGIOVIST 370
 AP BERLEX/SCHERING AG 662;102M
 SOLUTION; ORAL, RECTAL
GASTROVIST
 AA BERLEX/SCHERING AG 662;102M

DIATRIZOATE SODIUM (PAGE 3-54)

INJECTABLE; INJECTION
UROVIST SODIUM 300
 AP BERLEX/SCHERING AG 502M

GENTAMICIN SULFATE (PAGE 3-76)

INJECTABLE; INJECTION
ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER
TRAVENOL LABS EQ 0.8MG BASE/MLM
EQ 60MG BASE/100MLM

GONADORELIN HYDROCHLORIDE (PAGE 3-77)

INJECTABLE; INJECTION
FACTREL
AYERST LABS/AMHO EQ 0.1MG BASE/VIALM
EQ 0.5MG BASE/VIALM

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE (PAGE 3-77)

SOLUTION/DROPS; OPHTHALMIC
NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN
AT PHARMAFAIR, 0.025MG/ML; EQ 1.75MG BASE/ML;
AT 5,000 UNITS/MLM
0.025MG/ML; EQ 1.75MG BASE/ML;
10,000 UNITS/MLM

GUANABENZ ACETATE (PAGE 3-78)

TABLET; ORAL
WYTENSIN
WYETH LABS/AMHO EQ 4MG BASEM
EQ 6MG BASEM

HALOPERIDOL (PAGE 3-78)

> DLT > /CONCENTRATE; ORAL/
> DLT > /HALDOL/
> DLT > /MCNEIL LABORATORIES//2MG/ML/
> DLT > /INJECTABLE; INJECTION/
> DLT > /HALDOL/
> DLT > /MCNEIL LABORATORIES//2MG/ML/

> ADD > HALOPERIDOL LACTATE (PAGE 3-79)

> ADD > CONCENTRATE; ORAL
> ADD > HALDOL
> ADD > MCNEIL LABORATORIES EQ 2MG BASE/ML

> ADD > INJECTABLE; INJECTION
> ADD > HALDOL
> ADD > MCNEIL LABORATORIES EQ 5MG BASE/ML

HYALURONIDASE (PAGE 3-82)

INJECTABLE; INJECTION
/ALCANTARA/
/AB/ /SEARLE PHARMS/ /150 UNITS/VIAL/
WYDASE
/AB/ /WYETH LABS/AMHO/ /150 UNITS/VIAL/
WYETH LABS/AMHO 150 UNITS/VIAL

HYDRALAZINE HYDROCHLORIDE (PAGE 3-82)

TABLET; ORAL
HYDRALAZINE HCL
> ADD > AA PAR PHARMACEUTICALS 10MG
/AA/ /PREMO PHARM LABS/ /25MG/
/AA/ /50MG/
AA LEMMON 50MG

HYDROCORTISONE (PAGE 3-85)

LOTION; TOPICAL
NUTRACORT
/AT/ /OWEN LABS/ALCON LABS/0.52/
/AT/ /12/
AT OWEN LABS/DERM PRODS 0.52
AT 12
2.52M

> ADD > OINTMENT; TOPICAL
> ADD > AT NYMAO
NYC LABS 12M

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE (PAGE 3-88)

SOLUTION; OTIC
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE
AT PHARMAFAIR 12; EQ 3.5MG BASE/ML; 10,000 UNITS/MLM

HYDROCORTISONE BUTYRATE (PAGE 3-89)

> ADD > OINTMENT; TOPICAL
> ADD > LOCOID
> ADD > GIST-BROCADES/NETH 0.12M

HYDROXOCOBALAMIN (PAGE 3-90)

INJECTABLE; INJECTION
> DLT > /ALCANTARA/
> DLT > /AB/ /SEARLE LABS/AMHO/100MG/ML/
/WYETH LABS/AMHO/100MG/ML/

Original from
UNIVERSITY OF MICHIGAN

METHANTHLINE BROMIDE (PAGE 3-111)

~~INJECTABLE; INJECTION~~
~~BANTHINE~~
~~SEARLE/SEARLE PHARMS/50MG/VIAL~~

METHOCARBAMOL (PAGE 3-112)

TABLET; ORAL

METHOCARBAMOL

>_ADD> AA ASCOT HOSP. PHARMS 500MG
>_ADD> AA 750MG

METHYLCLOTHIAZIDE (PAGE 3-114)

TABLET; ORAL

METHYLCLOTHIAZIDE

AB MYLAN PHARMS 2.5MG
AB 5MG

METHYLPREDNISOLONE ACETATE (PAGE 3-115)

INJECTABLE; INJECTION

METHYLPREDNISOLONE ACETATE

>_ADD> BP MAURRY BIOLOGICAL 40MG/ML
>_ADD> BP 80MG/ML

METRONIDAZOLE (PAGE 3-117)

INJECTABLE; INJECTION

METRO T.V.

AP AM MCGAW/AM HOSP 500MG/100ML

TABLET; ORAL

METRONIDAZOLE

>_ADD> AB CHELSEA LABORATORIES 250MG
>_ADD> AB CORD LABORATORIES 250MG
>_ADD> AB 500MG
>_ADD> AB DANBURY PHARMACAL 250MG
/AB/ /LEHMAN/ /250MG/
AB METRYL
AB LEHMAN 250MG

MINOCYCLINE HYDROCHLORIDE (PAGE 3-118)

TABLET; ORAL

MINOCIN

LEDERLE LABS/AM CYAN ER 50MG BASE
Q 100MG BASE

NYSTATIN (PAGE 3-123)

ointment; TOPICAL

NYSTATIN

AT BYK-GULDEN 100,000 UNITS/GM

>_DLT> oxytetracycline hydrochloride (PAGE 3-125)

>_DLT>

>_DLT>

>_DLT>

~~TABLET; ORAL~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

~~oxytetracycline~~

OXYTETRACYCLINE HYDROCHLORIDE (PAGE 3-126)

CAPSULE; ORAL

OXYTETRACYCLINE HCL

/AB/ /LEDERLE LABS/AM CYAN ER 250MG BASE

PHENDIMETRAZINE TARTRATE (PAGE 3-132)

CAPSULE; ORAL

PHENDIMETRAZINE TARTRATE

/AB/ /CORP. LABORATORIES/ /25MG/

AA REID-PROVIDENT LABS 25MG

AA X-TROZINE

AA REXAR PHARMACAL 25MG

CAPSULE, CONTROLLED RELEASE; ORAL

MELFIAT-105

>_ADD> BC REID-PROVIDENT LABS 105MG

>_ADD> BC X-TROZINE L.A.

BC REXAR PHARMACAL 105MG

PHENTERMINE HYDROCHLORIDE (PAGE 3-133)

TABLET; ORAL

PHENTERMINE HCL

/AB/ /CORP. LABORATORIES/ /25MG/

AA REID-PROVIDENT LABS 25MG

PINDOLOL (PAGE 3-135)

TABLET; ORAL

VISKEN

SANDOZ PHARMS/SANDOZ 5MG

10MG

15MG

Digitized by Google

Original from
UNIVERSITY OF MICHIGAN

AT
PARACALINE
PRO PHARMA/STERI-MED 0.5%
0.5%

SULFAMETHOXAZOLE (PAGE 3-161)

TABLET; ORAL
SULFAMETHOXAZOLE
>_ADD> AB ASCOT HOSP PHARMS 500MG

SULFINPYRAZONE (PAGE 3-162)

CAPSULE; ORAL
ANTURANE
AB CIBA/CIBA-GEIGY 200MG
SULFINPYRAZONE
AB BARR LABORATORIES 200MG

TABLET; ORAL
SULFINPYRAZONE
AB BARR LABORATORIES 100MG

SULFISOXAZOLE (PAGE 3-162)

TABLET; ORAL
SULFISOXAZOLE
>_DLT> /BP/ /PREMO PHARM LABS/ /500MG/
>_ADD> BP LEMMON 500MG

TECHNETIUM, TC-99M, HEDRONATE KIT (PAGE 3-164)

INJECTABLE; INJECTION
AMERSCAN
AP AMERSHAM/RADIOCHEM N/A

TECHNETIUM, TC-99M, SULFUR COLLOID (PAGE 3-165)

INJECTABLE; INJECTION
TECHNETIUM TC 99M SULFUR COLLOID
/SYNCOPI INTL/ /PACI INTL/

THEOPHYLLINE (PAGE 3-168)

SYRUP; ORAL
SLO-PHYLLIN-80
/AA/ /DOONER LABORATORIES/ /80MG/15ML/
SLO-PHYLLIN
AA WILLIAM H RORER 80MG/15ML
TABLET; ORAL
SLO-PHYLLIN
/BP/ /DOONER LABORATORIES/ /100MG/
/BP/ /DOONER LABORATORIES/ /200MG/
/BP/ /DOONER LABORATORIES/ /200MG/
BD WILLIAM H RORER 100MG
BD 200MG

THEOPHYLLINE (PAGE 3-168)

TABLET, CONTROLLED RELEASE; ORAL
THEOCONTIN
PURDUE FREDERICK 400MG

THIAMINE HYDROCHLORIDE (PAGE 3-169)

INJECTABLE; INJECTION
THIAMINE HCL
>_ADD> AP MAURRY BIOLOGICAL 100MG/ML

TRIAMCINOLONE ACETONIDE (PAGE 3-173)

CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE
AT PHARMAFAIR 0.025%
AT 0.1%
AT 0.5%

LOTION; TOPICAL
KENALOG
AT ER SQUIBB AND SONS 0.025%
AT 0.1%
TRIAMCINOLONE ACETONIDE
AT NATL PHARM MFG/BARRE 0.025%
AT 0.1%

TRICHLORMETHIAZIDE (PAGE 3-174)

TABLET; ORAL
TRICHLORMETHIAZIDE
>_DLT> /BP/ /PREMO PHARM LABS/ /4MG/
>_ADD> BP LEMMON 4MG

TRIFLUOPERAZINE HYDROCHLORIDE (PAGE 3-175)

CONCENTRATE; ORAL
TRIFLUOPERAZINE
TFP

TRIMETHOBENZAMIDE HYDROCHLORIDE (PAGE 3-176)

INJECTABLE; INJECTION
TRIGAN
>_ADD> AP BEECHAM LABS/BEECHAM 100MG/ML
>_ADD> TRIMETHOBENZAMIDE HCL
>_ADD> AP CARTER-GLOGAU LABS 100MG/ML

Original from
UNIVERSITY OF MICHIGAN

ADDENDUM
DESI PENDING LIST
CUMULATIVE SUPPLEMENT NUMBER 2 / AUGUST '82 - OCTOBER '82

11

CURRENT STATUS - INEFFECTIVE

> DLT > /BETADINE/ /BUPROPE, PEPERIC/
> DLT > /FOLIC ACID/ /FOLIC ACID/
> DLT > DIPYRIDAMOLE /FRENCH PHARM LABS/
> ADD > LEMMON

CURRENT STATUS - 'EXEMPT' (COURT ORDER)

> DLT > BUTIBEL /HALLACE LABS/C-W/
> ADD > WALLACE LABS/C-W
> ADD > DIPYRIDAMOLE ASCOT HOSP PHARMS
> ADD > DIPYRIDAMOLE
> ADD > DIPYRIDAMOLE HALSEY DRUG
> ADD > DIPYRIDAMOLE
DIPYRIDAMOLE SUPERPHARM
DIPYRIDAMOLE
> ADD > HYBEPHEN BEECHAM LABS/BEECHAM
> ADD > ATROPINE SULFATE; HYOSCYAMINE SULFATE; PHENOBARBITAL;
> ADD > SCOPOLAMINE HYDROBROMIDE
ISOSORBIDE DINITRATE INWOOD LABS/FOREST
ISOSORBIDE DINITRATE
METHANDROSTENOLONE PAR PHARMACEUTICAL
METHANDROSTENOLONE
> ADD > NITRO-TIME TIME-CAP LABS
> ADD > NITROGLYCERIN
NITROGLYCERIN VITARINE/WEST CHEM
NITROGLYCERIN
NITROSTAT PARKE-DAVIS/W-L
NITROGLYCERIN

Digitized by Google

Original from
UNIVERSITY OF MICHIGAN

Digitized by Google

Original from
UNIVERSITY OF MICHIGAN



Digitized by Google

Original from
UNIVERSITY OF MICHIGAN